Since many patients with R/R DLBCL with high tumor bulk have experienced a transient reduction in tumor burden after intensive chemotherapy, we hypothesized that early treatment to reduce the tumor burden in such patients would improve the curative effects of anti-CD19-CAR-T therapy. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.